Tumor Metabolism

Organizer(s): Lewis C. Cantley, Karen H. Vousden and Jeffrey A. Engelman

Organized in collaboration with Cancer Research UK

Sponsored by Akebia Therapeutics and Cell Research

Summary of Meeting:

The fact that tumor cells have altered metabolism compared to their tissues of origin has been known for more than 90 years. Some commonly used chemotherapies, such as methotrexate, target metabolic enzymes. Over the past decade there has been a revival of interest in developing new therapies that target metabolic vulnerabilities of tumor cells. Dramatic improvements in technologies for monitoring tumor metabolism by mass spectrometry and by multiple modes of imaging have revealed that tumors evolve diverse alterations in metabolism in order to grow in the primary tissue and in metastatic sites. This conference will bring together scientists with a wide spectrum of expertise who are world leaders in this rapidly moving field. The conference includes talks from pharmaceutical scientists who are developing first-in-class drugs that target metabolic enzymes. In addition there will be presentations from academic scientists who are studying not only changes in metabolism in tumor cells, but also changes in metabolism in cells in the tumor microenvironment and in the whole body. The conference will also include poster sessions, short talks chosen from poster abstracts and plenty of time for discussion of each talk.

Scholarship Deadline: October 23 2018

Discounted Abstract Deadline: October 23 2018

Abstract Deadline: November 27 2018

Discounted Registration Deadline: January 8 2019

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support from these exhibitors at this conference:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novartis Institutes for BioMedical Research

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA232443-01
Funding for this conference was made possible (in part) by 1 R13 CA232443-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations